on Mainz BioMed N.V.
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data at ASCO 2024
Mainz Biomed N.V. will present new pooled colorectal cancer screening data at the ASCO 2024 Annual Meeting. This presentation will showcase findings from 690 subjects, making it the largest study to date for the company. The data, derived from the ColoFuture and eAArly DETECT studies, demonstrate a 92.3% sensitivity for detecting colorectal cancer and 82.3% for advanced precancerous lesions.
These studies utilized a novel combination of mRNA biomarkers, the Fecal Immunochemical Test (FIT), and a proprietary AI algorithm. This innovative approach aims to enhance diagnostic accuracy for colorectal cancer and advanced precancerous lesions. The poster presentation, led by Dr. D. Kim Turgeon, will take place on June 1, 2024.
Mainz Biomed's goal is to revolutionize colorectal cancer screening, potentially reducing cancer mortality rates globally. Additional details and updates can be found on the company's official website.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news